The WTC Health Program's $67.5M Research Pair Has a December 8 Deadline — and a Budget That Assumes Every Award Hits the Ceiling

Most research NOFOs give you a ceiling, a total, and an award count, and the three do not quite reconcile. The World Trade Center Health Program's FY2026 research pair reconciles perfectly — and the perfection is the most actionable thing about it.

Two companion opportunities, both administered by NIOSH through the CDC, both with a December 8, 2026 application deadline:

Now do the division.

$49.5 million divided by 30 U01 awards is $1.65 million each. That is exactly three years at $550,000 per year.

$18 million divided by 36 R21 awards is $500,000 each. That is exactly the R21 ceiling over two years.

Neither number is a coincidence, and neither is an average. NIOSH built both budgets on the assumption that every single award goes to the full ceiling for the full project period.

What that arithmetic means for your budget

Three consequences follow directly, and all three are counterintuitive relative to how most applicants approach a federal budget.

One: asking for less buys you nothing. The standard instinct — trim the budget to look efficient, signal fiscal responsibility, improve your odds — does not work against a pool sized at ceiling times count. A $1.2 million U01 request does not free money for another award in a way the agency has pre-committed to reward; it just funds your project with 27% less capacity for the same reporting burden. The award count is a budget-derived cap, not a judgment that will flex if applicants come in cheap.

Two: the award count is the real competition metric. Thirty U01s and thirty-six R21s are the ceiling on how many projects can be funded regardless of how many excellent applications arrive. There is no mechanism by which a strong cycle produces a thirty-first U01.

Three: budget to the ceiling and justify it completely. If the agency has already assumed you will spend $550,000 a year, a budget justification that reaches that number with defensible line items reads as a project correctly scoped to the mechanism. A budget that lands well under it invites the reviewer to ask whether the aims are large enough to warrant a U01 at all — in which case the R21 was the right mechanism and you applied to the wrong one.

December 8 is the middle cycle, not the deadline

This is the structural detail most likely to cost an applicant a cycle. RFA-OH-26-015 carries three application receipt dates:

• June 23, 2026
• December 8, 2026
• October 26, 2027

One RFA. One pooled budget of $18 million and 36 awards. Three chances to submit.

The June 23, 2026 cycle has already run. However many awards it consumed, the December 8 cycle competes for the residual — and the October 2027 cycle competes for whatever survives that. The totals printed on the opportunity listing are the RFA-lifetime figures, not the per-cycle figures.

That produces an asymmetry worth naming plainly. A multi-receipt-date RFA with a fixed pool structurally rewards early submission. If you have a fundable R21 idea and you are weighing December 8, 2026 against October 26, 2027 to buy more preparation time, you are trading proposal polish against a shrinking pool. For a program where the stated award count is 36 across all three dates — roughly a dozen per cycle if evenly distributed — that is usually a bad trade.

Before committing to the December 8 cycle, contact James Yiin's office and ask directly how many awards from the June 2026 cycle were made and what remains against the 36. Program officers answer this question. It is the single highest-value phone call available to an applicant here, and almost nobody makes it.

Where each mechanism wants you to go

The two RFAs are not two sizes of the same opportunity. They are pointed at different questions, and submitting to the wrong one is the most common avoidable error.

The U01 cooperative agreement seeks research across four major areas: linking exposure to the 9/11 attacks to health conditions; characterizing and treating established WTC-related conditions; health services research examining the effectiveness and efficiency of the Program's own healthcare delivery system; and impacts of 9/11 on job performance and occupational outcomes. The broader priority list spans screening methods, disease identification, treatment innovation, prevention, quality of life, genetic research, epidemiologic studies, healthcare access analysis, and investigation of emerging conditions potentially linked to 9/11 exposure.

Note the third area. Health services research on the Program's own delivery system is an invitation that sits oddly in a disease-research NOFO, and it is historically undersubscribed relative to clinical topics. An applicant with health services methods and access to Program administrative data is competing in a thinner field than one proposing another exposure-outcome cohort analysis.

The R21 is narrower and more specific: evidence-based strategies to improve treatment effectiveness, diagnostic practices, and program evaluation; lifestyle medicine research related to the Program; and studies focused solely on the Survivor population.

That last domain is the clearest signal in either document. The Program's membership reached 145,275 members as of June 30, 2026, split between responders and survivors — and survivors, the people who lived, worked, or attended school in the exposure zone rather than responding to it, have historically been the less-studied half. An R21 that is explicitly and only about survivors is responding to a named, deliberately carved-out priority. That is as close to a stated preference as a federal RFA produces.

Also worth noting what was removed: the Program discontinued a previously forecast U01 NOFO for Youth Research Cohort recruitment and retention, following input from the 9/11 community. If you built a concept around that forecast, it is gone, and the Program has said further updates on cohort development are forthcoming. Do not reshape that concept into the open U01 without talking to the program officer first — community input killed the line once.

Eligibility is unusually broad; one exclusion is absolute

Both RFAs accept applications from an unusually wide field: state, county, city, and tribal governments; public and private educational institutions; for-profit and nonprofit organizations; and small businesses. Cost sharing is not required for either.

The exclusion is categorical: non-U.S. entities and non-domestic components of U.S. organizations are not eligible. For a research area with substantial international interest in disaster-exposure epidemiology, that is a hard wall. A U.S. prime with a foreign component on the project team has an eligibility problem, not a budgeting problem.

Applications go through Grants.gov, not Simpler.Grants.gov, by 11:59 p.m. local applicant time on the deadline date. The R21 posted May 8, 2026 — a week after CDC's own May 1 advisory that the FY2026 NOFOs were still awaiting final approval and, if issued, would carry a compressed window of "approximately 45 days or less," with a return to standard timelines expected for FY2027. The three-receipt-date structure is how that compression was absorbed. Read it as a one-time accommodation rather than the Program's permanent shape.

The funding-authority question, answered carefully

There is a widely repeated reassurance about this Program that is true but narrower than it sounds. The 2015 reauthorization of the James Zadroga 9/11 Health and Compensation Act authorized the Health Program through 2090, and the 2019 legislation permanently funded the Victim Compensation Fund. That long horizon is real.

It does not mean the research line is insulated. Advocacy organizations have been pressing for the 9/11 Responder and Survivor Health Funding Correction Act precisely because the Program faces a projected funding shortfall against a growing and aging membership — the concern being waitlists, service reductions, and constrained new enrollment. A long authorization and a sufficient appropriation are different things.

And the near-term calendar is tight in a way applicants should price in. Federal funding runs at FY2026 levels only through December 11, 2026 under the continuing resolution signed September 3 — three days after this deadline. The same CR carries Section 157, which nullified OMB's Uniform Grants Regulation overhaul through that date. If that overhaul is finalized after December 11, an award issued in 2027 under this RFA could be administered under materially different termination and cost-allowability rules than the ones in effect when you wrote the budget.

That is not a reason to skip the cycle. It is a reason to write the project so that its first twelve months produce a self-contained, publishable result — which is good R21 design regardless, and increasingly good U01 design in the current environment.

The short version

Fall 2026 marks twenty-five years since September 11, 2001, and the research questions have shifted accordingly: aging, long-term mental health, quality of life, emerging conditions in a cohort now a quarter-century past exposure.

Against that, NIOSH has put $67.5 million on the table across two mechanisms with a shared December 8, 2026 deadline, a pool sized at exactly ceiling-times-count, three receipt dates drawing on one budget, and one explicitly carved-out priority — survivor-only studies — that most applicants will read past.

Budget to the ceiling. Call the program officer about the residual. And if your question is about survivors rather than responders, the R21 is where the Program has told you it is looking.